CA3122581C — Methods for imaging and treatment of somatostatin-receptor positive tumors
Assigned to Corcept Therapeutics Inc · Expires 2026-01-20 · 0y expired
What this patent protects
Methods for treating, identifying and localizing tumors expressing somatostatin receptors (SRs). including methods of enhancing the efficacy of imaging techniques by administration of a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (HKGRM) effective to incr…
USPTO Abstract
Methods for treating, identifying and localizing tumors expressing somatostatin receptors (SRs). including methods of enhancing the efficacy of imaging techniques by administration of a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (HKGRM) effective to increase SR expression in tumors. HKGRM administration for enhancing SR-based tumor imaging and treating neuroendocrine tumors. HKGRM and somatostatin or somatostatin analog combination therapy for treating and enhancing SR-based minor imaging.
Drugs covered by this patent
- Mifeprex (MIFEPRISTONE) · Corcept Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.